Subatomic and atomic crystallographic studies of aldose reductase: Implications for inhibitor binding

Cellular and Molecular Life Sciences

Volumn 61, Issue 7-8, 2004, Pages 763-773

  Podjarny, A ^a   Cachau, R E ^b   Schneider, T ^c,f   Van Zandt, M ^d   Joachimiak, A ^e  

^a INSTITUT DE GÉNÉTIQUE ET DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

^b SAIC FREDERICK INC   (United States)

^c UNIVERSITY OF GÖTTINGEN   (Germany)

^d The Institute for Diabetes Discovery   (United States)

^e ARGONNE NATIONAL LABORATORY   (United States)

^f FIRC INSTITUTE OF MOLECULAR ONCOLOGY   (Italy)

Author keywords

Aldose reductase inhibition; Subatomic resolution crystallography

Indexed keywords

ALDEHYDE REDUCTASE; ALDOSE REDUCTASE INHIBITOR; CARBOXYLATE INHIBITOR; CARBOXYLIC ACID; CHLORIDE ION; CYCLIC IMIDE INHIBITOR; FIDARESTAT; IDD 384; IDD 393; IDD 594; MINALRESTAT; PONALRESTAT; SNK 509; SORBINIL; TOLRESTAT; UNCLASSIFIED DRUG; WAY 509; ZOPOLRESTAT;

BINDING AFFINITY; BINDING AND RELATED PHENOMENA; CRYSTALLIZATION; CRYSTALLOGRAPHY; DRUG BINDING; DRUG MECHANISM; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITOR COMPLEX; ENZYME STRUCTURE; HUMAN; MASS SPECTROMETRY; NONHUMAN; OPTICAL RESOLUTION; PROTON TRANSPORT; REVIEW; STRUCTURE ACTIVITY RELATION;

ALDEHYDE REDUCTASE; CRYSTALLOGRAPHY, X-RAY; ENZYME INHIBITORS; HUMANS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; MOLECULAR STRUCTURE;

EID: 2442453293     PISSN: 1420682X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00018-003-3404-1     Document Type: Review

References (26)

1. Giacovazzo C., Monaco H., Viterbo D., Scordari F., Gilli G., Zanotti G. et al. (1992) Fundamentals of Crystallography. Oxford Univertiy Press, Oxford
2. Heinemann U., Illing G. and Oschkinat H. (2001) High-throughput three-dimensional protein structure determination. Curr. Opin. Biotechnol. 12: 348-354
3. Schulz W. G. (2001) Determining Structure. Chem. Eng. News 79: 23-26
4. Teeter M. M., Roe S. M. and Heo N. H. (1993) Atomic resolution (0.83 A) crystal structure of the hydrophobic protein crambin at 130 K. J. Mol. Biol. 230: 292-311
5. Jelsch C., Teeter M. M., Lamzin V., Pichon-Pesme V., Blessing R. H. and Lecomte C. (2000) Accurate protein crystallography at ultra-high resolution: valence electron distribution in crambin. Proc. Natl. Acad. Sci. USA 97: 3171-3176.
6. Kuhn P., Knapp M., Soltis M., Ganshaw G., Thoene M. and Bott R. (1998) The 0.78 Å Structure of a serine protease: Bacillus lentus subtilisin. Biochemistry 37: 13446-13452
7. Howard E., Lamour V., Mitschler A., Barth P., Moras D. and Podjarny A. (1999) Resolution improvement to 0.9A in crystals of human aldose reductase. Acta Cryst. A55 Suppl. P09.OB.001
8. Dauter Z., Lamzin V. S. and Wilson K. S. (1997) The benefits of atomic resolution. Curr. Opin. Struct. Biol. 7: 681-688.
9. Esposito L., Vitagliano L. and Mazzarella L. (2002) Recent advances in atomic resolution protein crystallography. Protein Peptide Lett. 9: 95-105
10. Schmidt A. and Lamzin V. S. (2002) Veni, vidi, vici -atomic resolution unraveling the mysteries of protein function. Curr. Opin. Struct. Biol. 12: 698-703
11. Cachau R., Howard E., Barth P., Mitschler A., Chevrier B., Lamour V. et al. (2000) The subatomic resolution structure of human aldose reductase shows the catalytic mechanism. Journal de Physique 10: 3-13
12. El-Kabbani O., Darmanin C., Schneider T. R., Hazemann I., Ruiz F., Oka M. et al. (2003) Ultra-high resolution drug design II: atomic resolution structures of human aldose reductase holoenzyme complexed with fidarestat and minalrestat; implications for the binding of cyclic imide inhibitors. Proteins Struct. Funct. Genet. In press
13. El-Kabbani O., Ramsland P., Darmanin C., Chung R. P. T. and Podjarny A. (2003) Structure of human aldose reductase holoenzyme in complex with statil: An approach to structure-based inhibitor design of the enzyme. Proteins Struct. Funct. Genet. 50: 230-238
14. Lamour V., Barth P., Rogniaux H., Poterszman A., Howard E., Mitschler A. et al. (1999) Production of crystals of human aldose reductase with very high resolution diffraction. Acta Crystallogr. D D55: 721-723.
15. Rossmann M. Ed. (1972) The molecular Replacement method. A Collection of papers on the Use of Non-Crystallographic Symmetry. Gordon and Breach, New York
16. Navaza J. (1994) Amore an automated package for molecular replacement. Acta Cryst. Section A 50: 157-163
17. Miyamoto S. (2002). Recent advances in aldose reductase inhibitors: potential agents for the treatment of diabetic complications. Expert. Opin. Ther. Patents 12: 621-631
18. Oates P. J. and Mylari B. L. (1999) Aldose reductase inhibitors: therapeutic implications for diabetic complications. Expert Opin Investig Drugs 8: 2095-2119
19. Urzhumtsev A., Tete-Favier F., Mitschler A., Barbanton J., Barth P., Urzhumtseva L. et al. (1997) A 'specificity' pocket inferred from the crystal structures of the complexes of aldose reductase with the pharmaceutically important inhibitors tolrestat and sorbinil. Structure 5: 601-612
20. Rick S. W. and Cachau R. E. (2000) The nonplanarity of the peptide group: molecular dynamics simulations with a polarizable two-state model for the peptide bond. J. Chem. Phys. 112: 5230-5241
21. McCammon J. A. (1991) Free energy from simulations. Curr. Opin. Struct. Biol. 1: 196-200
22. Wilson D. K., Tarle I., Petrash J. M. and Quiocho F. A. (1993) Refined 1.8 A structure of human aldose reductase complexed with the potent inhibitor zopolrestat. Proc. Natl. Acad. Sci. USA 90: 9847-9851
23. Calderone V., Chevrier B., Van Zandt M., Lamour V., Howard E., Poterszman A. et al. (2000) The structure of human aldose reductase bound to the inhibitor IDD384. Acta Crystallogr. D D56: 536-540
24. Oka M., Matsumoto Y., Sugiyama S., Tsuruta N. and Matsushima M. (2000) A potent aldose reductase inhibitor, (2S,4S)-6-fluoro-2′,5′-dioxospiro chroman-4,4′-imidazolidine -2-carboxamide (Fidarestat): its absolute configuration and interactions with the aldose reductase by X-ray crystallography. J. Med. Chem. 43: 2479-2483.
25. Howard E., Sanishvili R., Cachau R., Mitschler A., Chevrier B., Barth P. et al. (2003) Ultra-high resolution drug design I: details of interactions in human aldose reductase-inhibitor complex at 0.66 Å. Prot. Struct. Funct. Genet., in press
26. Podjarny A., Schneider T. R., Cachau R. E., Joachimiak A. (2003) Structural information content at high resolution: MAD versus native. Methods Enzymol. 374: 321-341